Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.65 |
| ▸ | EGFR | P00533 | 17/20 | 0.62 |
| ▸ | GAK | O14976 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.59 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.59 |
| ▸ | BUB1 | O43683 | 2/20 | 0.59 |
| ▸ | STK10 | O94804 | 2/20 | 0.59 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.59 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.59 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.59 |
| ▸ | PLK4 | O00444 | 1/20 | 0.59 |
| ▸ | CIT | O14578 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1507704 | 0.99 | FBP1 (0.64) | FBP1EGFRGAKALDH1A1MAPT | |
| SCHEMBL1507694 | 0.86 | EGFR (0.57) | FBP1EGFRGAKALDH1A1MAPT | |
| SCHEMBL1507536 | 0.84 | EGFR (0.55) | FBP1EGFRGAKALDH1A1MAPT | |
| SCHEMBL1507619 | 0.83 | EGFR (0.63) | FBP1EGFRGAKALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1507675 | 0.83 | FBP1 (0.62) | FBP1EGFRGAKALDH1A1MAPT | |
| SCHEMBL27529543 | 0.82 | EGFR (0.69) | FBP1EGFRGAKALDH1A1MAPT | |
| SCHEMBL1507524 | 0.82 | EGFR (0.74) | FBP1EGFRGAKALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1507507 | 0.81 | EGFR (0.67) | FBP1EGFRGAKALDH1A1MAPT | |
| SCHEMBL7982823 | 0.81 | EGFR (0.68) | FBP1EGFRGAKALDH1A1MAPT | |
| SCHEMBL1507464 | 0.81 | EGFR (0.70) | FBP1EGFRGAKALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | claimed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | claimed |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2015-02-26 | — | — | US | claimed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | claimed |
| US-8163287-B2 | Combination therapy of her expressing tumors | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | claimed |
| EP-2344543-A2 | TREATMENT METHOD | Genentech, Inc. (US) | 2011-07-20 | — | — | EP | claimed |
| WO-2010045344-A1 | COMBINATION THERAPY COMPRISING A C-MET ANTAGONIST AND A VEGF ANTAGONIST | GENENTECH, INC. (US) | 2010-04-22 | — | — | WO | claimed |
| WO-2010045345-A2 | TREATMENT METHOD | GENENTECH, INC. (US) | 2010-04-22 | — | — | WO | claimed |
| US-RE41065-E1 | Alkynl and azido-substituted 4-anilinoquinazolines | PFIZER, INC. (US) | 2009-12-29 | — | — | US | claimed |
| US-20090226443-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH, INC. (US) | 2009-09-10 | — | — | US | claimed |
| US-20080175797-A1 | PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-07-24 | — | — | US | claimed |
| WO-2007013950-A9 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH INC (US) | 2007-03-29 | — | — | WO | claimed |
| WO-2007013950-A2 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2007-02-01 | — | — | WO | claimed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | claimed |
| EP-0817775-B1 | QUINAZOLINE DERIVATIVES | PFIZER (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1110953-A1 | Quinazoline derivatives | PFIZER INC. (US) | 2001-06-27 | — | — | EP | claimed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | claimed |
| EP-0817775-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1998-01-14 | — | — | EP | claimed |
| WO-1996030347-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1996-10-03 | — | — | WO | claimed |
| EP-3103799-A1 | QUINAZOLINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | disclosed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2015-02-26 | — | — | US | disclosed |
| EP-1853300-B1 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | GENENTECH INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20130005726-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2013-01-03 | — | — | US | disclosed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8163287-B2 | Combination therapy of her expressing tumors | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110262436-A1 | TREATMENT METHOD | GENENTECH, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011112588-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-2344543-A2 | TREATMENT METHOD | Genentech, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2295415-A1 | Quinazoline derivatives | OSI Pharmaceuticals, Inc. (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2257293-A2 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | Genentech, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2010120387-A1 | OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010045344-A1 | COMBINATION THERAPY COMPRISING A C-MET ANTAGONIST AND A VEGF ANTAGONIST | GENENTECH, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045345-A2 | TREATMENT METHOD | GENENTECH, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| EP-2163546-A1 | Quinazoline derivatives | Pfizer Products Incorporated (US) | 2010-03-17 | — | — | EP | disclosed |
| US-RE41065-E1 | Alkynl and azido-substituted 4-anilinoquinazolines | PFIZER, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| WO-2009111691-A2 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226443-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2009103076-A1 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY OF RTK INHIBITORS | OXIGENE, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090209496-A1 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY OF RTK INHIBITORS | OXIGENE, INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090155247-A1 | Methods of Using Death Receptor Agonists and EGFR Inhibitors | ASHKENAZI AVI J | 2009-06-18 | — | — | US | disclosed |
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1859793-A1 | NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | disclosed |
| EP-1853300-A2 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | Genentech, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007013950-A9 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH INC (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007013950-A2 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006089015-A2 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | GENENTECH, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-0817775-B1 | QUINAZOLINE DERIVATIVES | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1110953-A1 | Quinazoline derivatives | PFIZER INC. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | disclosed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | FBP1 3954/4885EGFR 1/4885GAK 3124/4885 |
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EGFR, KIT, ERBB2 | FBP1 2793/4885EGFR 1/4885GAK 869/4885 |
| US-20090155247-A1 | Methods of Using Death Receptor Agonists and EGFR Inhibitors | EGFR, ERBB4, TNFRSF9 | FBP1 3954/4885EGFR 1/4885GAK 3124/4885 |
| US-20090209496-A1 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY OF RTK INHIBITORS | KDR, EGFR, FLT1 | FBP1 1954/4885EGFR 2/4885GAK 440/4885 |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | FBP1 2318/4885EGFR 2/4885GAK 1055/4885 |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | FBP1 3954/4885EGFR 1/4885GAK 3124/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | FBP1 2318/4885EGFR 2/4885GAK 1055/4885 |
| US-20090226443-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | FBP1 3214/4885EGFR 2/4885GAK 1255/4885 |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | FBP1 3214/4885EGFR 2/4885GAK 1255/4885 |
| US-20110262436-A1 | TREATMENT METHOD | HGF, HDGF, FGF2 | FBP1 2775/4885EGFR 6/4885GAK 2925/4885 |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | FBP1 3214/4885EGFR 2/4885GAK 1255/4885 |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | FBP1 2489/4885EGFR 129/4885GAK 162/4885 |
| US-20080175797-A1 | PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS | EGFR, MUC1, OGFR | FBP1 3616/4885EGFR 1/4885GAK 1209/4885 |
| US-20130005726-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | NOD2, RIPK2, RIPK1 | FBP1 2963/4885EGFR 2498/4885GAK 510/4885 |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | FBP1 2318/4885EGFR 2/4885GAK 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.